{"disease":{"id":"primary-intraocular-lymphoma","name":"primary intraocular lymphoma"},"drugs":{"marketed":[],"pipeline":[],"offLabel":[],"totalMarketed":0,"totalPipeline":0},"trials":{"data":[{"nct_id":"NCT06973811","title":"ZR-MTX for PIOL Phase II Trial","phase":"PHASE2","overall_status":"NOT_YET_RECRUITING","enrollment_count":47,"lead_sponsor_name":"Peking Union Medical College Hospital","has_results":false},{"nct_id":"NCT03746223","title":"Intravitreal Methotrexate and R2(Rituximab & Lenalidomide) Regimen in Newly-diagnosed Primary Vitreoretinal Lymphoma","phase":"PHASE2","overall_status":"UNKNOWN","enrollment_count":42,"lead_sponsor_name":"Peking Union Medical College Hospital","has_results":false}],"total":2},"guidelines":[],"source":"Drug Landscape verified database"}